/
/
/

Tatva Chintan Pharma Chem Results

Financial overview

CAGR%
Sales
Profits
Returns
ROE
10Y5Y3YTTM
-11%6%32%
--4%-3%636%
--5%-2%49%
19%10%4%6%

Peer Comparison

Symbol
SOLARINDS
PIDILITIND
SRF
FLUOROCHEM
NAVINFLUOR
GODREJIND
DEEPAKNTR
AETHER
ATUL
AARTIIND
TATVA
PriceM.Cap (₹)PE RatioEPS (₹)EV/EBITDAAnnual PAT
21,445₹193746 Cr97.2972.11250.42₹1678 Cr
1,629.5₹166118 Cr62.718.5729.91₹2449 Cr
2,547₹77219 Cr35.7225.6102.33₹1835 Cr
4,554₹51537 Cr83.820.0990.49₹577 Cr
8,557.5₹44624 Cr56.5147.43184.25₹664 Cr
1,173₹38937 Cr33.128.4450.37₹1241 Cr
1,712.4₹23559 Cr30.0825.2974.81₹551 Cr
1,625.6₹21984 Cr93.474.7323.27₹219 Cr
6,386₹19036 Cr23.9383.32378.24₹678 Cr
492.05₹18200 Cr34.274.2827.98₹419 Cr
1,678.5₹3740 Cr72.796.8338.4₹42 Cr

Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022Dec 2021Sep 2021Jun 2021Mar 2021Dec 2020Sep 2020Jun 2020
₹167 Cr₹134 Cr₹131 Cr₹124 Cr₹117 Cr₹108 Cr₹86 Cr₹83 Cr₹105 Cr₹98 Cr₹84 Cr₹97 Cr₹114 Cr₹125 Cr₹121 Cr₹90 Cr₹88 Cr₹99 Cr₹105 Cr₹124 Cr₹107 Cr₹109 Cr₹80 Cr₹60 Cr₹52 Cr
₹3 Cr-₹35 L₹2 Cr₹1 Cr₹1 Cr₹72 L₹4 L₹38 L₹1 Cr₹5 Cr₹1 Cr₹76 L₹1 Cr₹85 L₹1 Cr₹2 Cr₹2 Cr₹31 L₹5 Cr₹3 Cr₹3 Cr₹3 Cr₹66 L₹2 Cr₹17 L
₹170 Cr₹134 Cr₹133 Cr₹125 Cr₹118 Cr₹109 Cr₹86 Cr₹84 Cr₹107 Cr₹103 Cr₹85 Cr₹97 Cr₹115 Cr₹125 Cr₹122 Cr₹92 Cr₹90 Cr₹99 Cr₹109 Cr₹127 Cr₹110 Cr₹111 Cr₹81 Cr₹62 Cr₹52 Cr
₹145 Cr₹116 Cr₹115 Cr₹110 Cr₹109 Cr₹106 Cr₹86 Cr₹85 Cr₹100 Cr₹89 Cr₹80 Cr₹83 Cr₹99 Cr₹111 Cr₹105 Cr₹81 Cr₹76 Cr₹79 Cr₹83 Cr₹90 Cr₹83 Cr₹86 Cr₹57 Cr₹55 Cr₹43 Cr
₹35 Cr₹28 Cr₹27 Cr₹23 Cr₹18 Cr₹10 Cr₹7 Cr₹6 Cr₹14 Cr₹20 Cr₹12 Cr₹21 Cr₹22 Cr₹17 Cr₹19 Cr₹13 Cr₹17 Cr₹22 Cr₹29 Cr₹39 Cr₹29 Cr₹27 Cr₹25 Cr₹8 Cr₹11 Cr
₹2 Cr₹1 Cr₹49 L₹51 L₹41 L₹39 L₹42 L₹17 L₹31 L₹21 L₹38 L₹3 Cr₹3 Cr₹3 Cr₹2 Cr₹2 Cr₹1 Cr₹1 Cr₹99 L₹1 Cr₹3 Cr₹1 Cr₹1 Cr₹99 L₹50 L
₹21 Cr₹17 Cr₹18 Cr₹14 Cr₹9 Cr₹2 Cr-₹24 L-₹1 Cr₹7 Cr₹14 Cr₹5 Cr₹11 Cr₹13 Cr₹8 Cr₹14 Cr₹9 Cr₹14 Cr₹19 Cr₹25 Cr₹35 Cr₹24 Cr₹24 Cr₹22 Cr₹6 Cr₹8 Cr
₹16 Cr₹10 Cr₹15 Cr₹10 Cr₹7 Cr₹1 Cr₹14 L-₹66 L₹5 Cr₹10 Cr₹3 Cr₹8 Cr₹10 Cr₹17 Cr₹12 Cr₹7 Cr₹10 Cr₹18 Cr₹23 Cr₹32 Cr₹23 Cr₹21 Cr₹21 Cr₹4 Cr₹7 Cr

Balance Sheet

Consolidated
Standalone
%
Name
Equity And Liabilities
Share Capital
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Secured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Currents Investments
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018
₹23 Cr₹23 Cr₹23 Cr₹22 Cr₹22 Cr₹20 Cr₹8 Cr₹8 Cr₹8 Cr
₹758 Cr₹715 Cr₹714 Cr₹493 Cr₹451 Cr₹146 Cr₹110 Cr₹72 Cr₹54 Cr
₹758 Cr₹715 Cr₹714 Cr₹493 Cr₹451 Cr₹146 Cr₹110 Cr₹72 Cr₹54 Cr
₹782 Cr₹739 Cr₹737 Cr₹515 Cr₹473 Cr₹166 Cr₹118 Cr₹80 Cr₹62 Cr
₹5 Cr₹0₹64 L₹4 Cr₹13 Cr₹27 Cr₹39 Cr₹32 Cr₹20 Cr
-₹10 Cr-₹13 Cr-₹12 Cr-₹16 Cr-₹9 Cr₹2 Cr₹4 Cr₹3 Cr₹2 Cr
₹1 Cr₹0₹0₹0₹80,000₹1 Cr₹3 L₹4 L₹52 L
₹3 Cr₹1 Cr₹1 Cr₹1 Cr₹65 L₹55 L₹40 L₹29 L₹0
-₹77 L-₹11 Cr-₹10 Cr-₹11 Cr₹5 Cr₹31 Cr₹44 Cr₹35 Cr₹22 Cr
₹58 Cr₹33 Cr₹45 Cr₹32 Cr₹45 Cr₹47 Cr₹32 Cr₹22 Cr₹25 Cr
₹40 Cr₹25 Cr₹24 Cr₹50 Cr₹33 Cr₹21 Cr₹15 Cr₹11 Cr₹2 Cr
₹114 Cr₹36 Cr₹10 Cr₹156 Cr₹92 Cr₹49 Cr₹40 Cr₹40 Cr₹36 Cr
₹87 L₹3 Cr₹56 L₹2 Cr₹1 Cr₹11 Cr₹6 L₹4 L₹0
₹213 Cr₹96 Cr₹80 Cr₹241 Cr₹171 Cr₹128 Cr₹88 Cr₹73 Cr₹63 Cr
₹994 Cr₹824 Cr₹807 Cr₹744 Cr₹649 Cr₹325 Cr₹249 Cr₹188 Cr₹147 Cr
₹12 Cr₹7 Cr₹6 Cr₹1 Cr₹3 Cr₹51 L₹68 L₹43 L₹0
₹120 Cr₹36 Cr₹14 Cr₹170 Cr₹120 Cr₹90 Cr₹91 Cr₹77 Cr₹56 Cr
₹733 Cr₹617 Cr₹488 Cr₹232 Cr₹186 Cr₹139 Cr₹122 Cr₹73 Cr₹70 Cr
₹123 Cr₹89 Cr₹61 Cr₹36 Cr₹27 Cr₹18 Cr₹11 Cr₹7 Cr₹13 Cr
₹609 Cr₹529 Cr₹427 Cr₹196 Cr₹160 Cr₹120 Cr₹111 Cr₹67 Cr₹56 Cr
₹23 Cr₹22 Cr₹73 Cr₹231 Cr₹51 Cr₹10 Cr₹5 Cr₹6 Cr₹10 Cr
₹4 Cr₹0₹0₹0₹0₹0₹0₹0₹47 L
₹4 Cr₹0₹0₹0₹0₹0₹0₹0₹47 L
₹5 Cr₹4 Cr₹4 Cr₹3 Cr₹2 Cr₹30 L₹17 L₹38 L₹17 L
₹2 Cr₹1 Cr₹83 L₹55 L₹51 L₹0₹0₹0₹0
₹645 Cr₹558 Cr₹509 Cr₹430 Cr₹214 Cr₹131 Cr₹116 Cr₹73 Cr₹67 Cr
₹0₹0₹10 Cr₹0₹0₹0₹0₹0₹50 L
₹196 Cr₹134 Cr₹153 Cr₹162 Cr₹170 Cr₹72 Cr₹64 Cr₹36 Cr₹29 Cr
₹119 Cr₹90 Cr₹70 Cr₹84 Cr₹57 Cr₹91 Cr₹50 Cr₹41 Cr₹32 Cr
₹9 Cr₹14 Cr₹38 Cr₹45 Cr₹177 Cr₹5 Cr₹11 Cr₹16 Cr₹9 Cr
₹8 Cr₹6 Cr₹7 Cr₹5 Cr₹5 Cr₹6 Cr₹3 Cr₹4 Cr₹1 Cr
₹18 Cr₹21 Cr₹20 Cr₹17 Cr₹27 Cr₹20 Cr₹6 Cr₹18 Cr₹9 Cr
₹350 Cr₹265 Cr₹298 Cr₹314 Cr₹436 Cr₹195 Cr₹133 Cr₹114 Cr₹80 Cr
₹136 Cr₹169 Cr₹218 Cr₹74 Cr₹264 Cr₹66 Cr₹45 Cr₹42 Cr₹18 Cr
₹994 Cr₹824 Cr₹807 Cr₹744 Cr₹649 Cr₹325 Cr₹249 Cr₹188 Cr₹147 Cr
₹334₹316₹315₹232₹213₹83₹146₹99₹77
₹334₹316₹315₹232₹213₹83₹59₹40₹31

Cash Flow

Consolidated
Standalone
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Effect of Foreign Exchange Fluctuations
Closing Cash & Cash Equivalent
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018
₹57 Cr₹8 Cr₹44 Cr₹45 Cr₹104 Cr₹61 Cr₹48 Cr₹27 Cr₹0
₹44 Cr₹29 Cr₹29 Cr₹17 Cr₹12 Cr₹7 Cr₹9 Cr₹8 Cr₹0
-₹62 Cr-₹8 Cr₹34 Cr-₹24 Cr-₹77 Cr-₹38 Cr-₹23 Cr-₹22 Cr₹0
₹39 Cr₹29 Cr₹107 Cr₹37 Cr₹39 Cr₹30 Cr₹34 Cr₹13 Cr₹0
₹31 Cr₹25 Cr₹98 Cr₹28 Cr₹20 Cr₹20 Cr₹25 Cr₹7 Cr₹0
-₹116 Cr-₹65 Cr-₹121 Cr-₹101 Cr-₹197 Cr-₹21 Cr-₹40 Cr-₹17 Cr₹0
₹79 Cr₹17 Cr₹31 Cr₹38 Cr₹235 Cr-₹5 Cr₹10 Cr₹17 Cr₹0
-₹5 Cr-₹24 Cr₹8 Cr-₹36 Cr₹59 Cr-₹6 Cr-₹5 Cr₹8 Cr₹0
₹11 Cr₹35 Cr₹27 Cr₹63 Cr₹4 Cr₹10 Cr₹16 Cr₹8 Cr₹0
-₹19 L₹9 L-₹8 L-₹9 L-₹2 L₹0₹0₹0₹0
₹6 Cr₹11 Cr₹35 Cr₹27 Cr₹63 Cr₹4 Cr₹11 Cr₹16 Cr₹0

Fundamental Ratios

Consolidated
Standalone
Empty box

No results found

Share Price Live Stats

Open (₹)1,609.90
Volume (₹)85,803.00
High (₹)1,688.00
Upper Circuit1,915.40
Low (₹)1,580.10
Lower Circuit1,277.00
Prev Close1,596.20
52W High (₹)1,838.10
Price1,678.50
52W Low (₹)976.40

Share Market Cap & Key Ratios Overview

M.Cap (₹)3740.39 Cr
Div. Yield (%)0.13
PE Ratio72.79
Debt to Equity0.15
Price to Book3.14
Book Value334.20
EPS (TTM)21.97
Face Value10.00
ROE (%)5.53

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .

Peer Stocks

1 week
1 month
1 year
Name
SOLARINDSNSE
PIDILITINDNSE
SRFNSE
FLUOROCHEMNSE
NAVINFLUORNSE
GODREJINDNSE
DEEPAKNTRNSE
AETHERNSE
ATULNSE
AARTIINDNSE
TATVANSE
LTP
1W Low
1W High
Market cap (₹)
21445+1045 (5.12%)
19810
21695
1,93,746Cr
1629.5+0 (0.00%)
1612.40
1687.70
1,66,118Cr
2547-42.9 (-1.66%)
2532.20
2648
77,219Cr
4554-217.2 (-4.55%)
4461.10
4850
51,537Cr
8557.5+40 (0.47%)
8275.50
8740
44,624Cr
1173+5.5 (0.47%)
1128.50
1215.90
38,937Cr
1712.4-50.5 (-2.86%)
1705.70
1820
23,559Cr
1625.6-71.2 (-4.20%)
1614.30
1707.80
21,984Cr
6386-73.5 (-1.14%)
6358
6642.50
19,036Cr
492.05-48.3 (-8.94%)
490
540.60
18,200Cr
1678.5+48.5 (2.98%)
1563.60
1688
3,740Cr

Tatva Chintan Pharma Chem Ltd Annual Results Key Takeaways

Operating profit (before other income, interest and exceptional items) was ₹35.08Cr; with other income of ₹2.78Cr, profit before interest and tax came to ₹23.19Cr. Interest expense was ₹2.08Cr; PBT before exceptional items stood at ₹21.11Cr. Cost mix (full year): raw materials ₹176.74Cr; employee cost ₹52.92Cr; depreciation ₹10.57Cr; other expenses ₹134.76Cr. Basis: consolidated annual results.

Tatva Chintan Pharma Chem Ltd Quaterly Results Key Takeaways

Tatva Chintan Pharma Chem Ltd reported ₹167.06Cr total income from operations in Jun 2026, softer than ₹134.14Cr in Mar 2026 but higher than ₹116.86Cr in Jun 2025. Operating profit (before other income, interest and exceptional items) was ₹35.08Cr; with other income of ₹2.78Cr, profit before interest and tax came to ₹23.19Cr. Interest expense was ₹2.08Cr, taking profit before tax to ₹21.11Cr. After tax of ₹5.13Cr, profit after tax stood at ₹15.98Cr (vs ₹10.32Cr in Mar 2026 and ₹6.65Cr in Jun 2025).